Iterum Therapeutics shares surge 10.73% premarket after business update highlights expanded distribution, Medicare rebate agreement, and European patent approval.

Iterum Therapeutics surged 10.73% in premarket trading following a business update highlighting expanded market access and intellectual property developments. The company announced that its antibiotic ORLYNVAH™ is now stocked at Cencora (formerly AmerisourceBergen), in addition to McKesson, enhancing physician access. Additionally, a rebate agreement with a top-three Medicare Part D pharmacy benefit manager positions ORLYNVAH™ for formulary inclusion as early as Q1 2026, broadening its patient reach. The European Patent Office also signaled intent to grant a patent for a bilayer tablet formulation of its drug, extending exclusivity until 2039. These developments—improved distribution, Medicare coverage potential, and IP protection—collectively strengthened investor confidence in Iterum’s commercialization prospects for its flagship product.